Conferences
Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Hematology
Lymphoma
Leukemia
Lung Cancers
Melanoma
Prostate Cancer
Urology
CLL
Precision Medicine
Supportive Care
More...
Giants Cancer Care

Dr. Younes Discusses the Future of Treating Lymphoid Malignancies

Anas Younes, MD
Published Online: Tuesday, May 6, 2014
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of treating lymphoid malignancies.

In a session at the 18th Annual International Congress on Hematologic Malignancies®, oncologists discussed how to select patients with lymphoid malignancies for therapy in this era of molecularly-defined subsets of disease. Though tools exist to define mutations in certain diseases, they are not yet guiding therapy in lymphoid malignancies. Younes says he believes this is the future.

There remains a need to learn more about disease subsets and place patients in clinical trials to personalize treatments. This movement from treating all patients with R-CHOP to dissecting disease and offering treatments accordingly will represent a culture change.

Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
 
$auto_registration$